✨ Free AI Report
Fennec Pharmaceuticals Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Fennec Pharmaceuticals Inc.
Company Research

Fennec Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. PEDMARK was commercia...

Analyst-debate audio for Fennec Pharmaceuticals Inc.

AskCyborg analysts argue the bull and bear cases for Fennec Pharmaceuticals Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Specialty pharma company with a first-to-market, approved orphan drug showing strong commercial traction, patent protection, and...

Read the full analyst-debate transcript →
Industry Biotechnology
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Fennec Pharmaceuticals Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Fennec Pharmaceuticals Inc. Overview

Pro stress-test →

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. PEDMARK was commercially launched in the United States in October 2022 and has since achieved significant market traction. The company addresses a critical unmet medical need for children receiving cisplatin chemotherapy who face permanent hearing loss.

Strategic Profile

Pro stress-test →

PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. In March 2026, the company settled PEDMARK patent litigation with Cipla, which restricted generic entry until September 1, 2033, providing substantial market exclusivity. The company has focused on expanding PEDMARK's clinical and commercial footprint, including investigator-initiated studies and real-world evidence generation.

Competitive Landscape

Pro stress-test →

PEDMARK provides the first and only FDA-approved treatment specifically designed to help protect hearing in children and young adults after receiving cisplatin. As a first-to-market orphan drug with exclusive indications, Fennec faces limited direct competition in the pediatric ototoxicity protection space. However, the company competes broadly within the oncology supportive care market and faces potential competition from off-label use of generic sodium thiosulfate.

Industry Context

Fennec Pharmaceuticals Inc. operates in Biotechnology.

Key facts

Founded: 1996 · Headquarters: Research Triangle Park, North Carolina

What the analysts stress-tested

The top findings that survived the multi-agent debate for Fennec Pharmaceuticals Inc..

  • Four abstracts evaluating PEDMARK were accepted to the 2026 ASCO Annual Meeting (May 29–June 2, 2026), demonstrating ongoing clinical validation
  • Patent litigation settlement with Cipla extends generic exclusivity to September 1, 2033, providing long-term competitive moat
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Four abstracts on PEDMARK accepted to ASCO 2026 Annual Meeting
  • March 2026Patent litigation settlement with Cipla securing exclusivity until September 2033
  • +2 moreTrack every material event for Fennec Pharmaceuticals Inc. as it happens. Explore monitoring →
Get alerted when Fennec Pharmaceuticals Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Generic Sodium ThiosulfateOff-label use in chemotherapy support→Standard Oncology Supportive CareHearing protection via other modalities→

Compare Fennec Pharmaceuticals Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Fennec Pharmaceuticals Inc. operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about Fennec Pharmaceuticals Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Fennec Pharmaceuticals Inc. and its top competitor on Cyborg Score”
“What did Fennec Pharmaceuticals Inc. do this quarter?”
“Is Fennec Pharmaceuticals Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Fennec Pharmaceuticals Inc. do?+
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. PEDMARK was commercia...
What is Fennec Pharmaceuticals Inc.'s Cyborg Score?+
Fennec Pharmaceuticals Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Fennec Pharmaceuticals Inc.'s main competitors?+
Named competitors include Generic Sodium Thiosulfate, Standard Oncology Supportive Care. The full competitive landscape is in the AskCyborg report.
How can I get the full Fennec Pharmaceuticals Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Fennec Pharmaceuticals Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Fennec Pharmaceuticals Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score